Please login to the form below

Not currently logged in
Email:
Password:

New Merck Foundation appoints Rasha Kelej

She takes up role as CEO of the pharma firm's newly-established non-profit

Rasha KelejRasha Kelej has been appointed chief executive officer for Merck KGaA’s non-profit limited liability company, The Merck Foundation.

Prior to her new position at The Merck Foundation, Kelej has held numerous roles at Merck, including vice president, head of global business for Merck Serono, chief social officer for Merck Group, and subsequently as its senior vice president.

She said: “The Merck Foundation will focus on initiatives that will contribute towards the Sustainable Development Goals outlined by the United Nations.

“To achieve the foundation’s goals, we will develop and implement coherent strategies, result-oriented programs and initiatives, provide grants to support projects and help raise funds where needed.”

Chairman of the board of trustees for The Merck Foundation, Frank Stangenberg-Haverkamp, added: “The vision of the new foundation is a world where everyone can lead a healthy and fulfilling life, also those living under disadvantaged conditions.

“With The Merck Foundation we will continue our commitment towards improving access to innovative healthcare solutions in underserved communities, building healthcare and scientific research capacity and advancing people’s lives through science and technology.”

The Foundation will be chaired by Stangenberg-Haverkamp and he will advise and monitor its performance.

28th June 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...